Combined Therapy of Low-Dose Angiotensin Receptor-Neprilysin Inhibitor and Sodium-Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects

• Main Authors: Donghyun Kim (Author), Gyuho Jang (Author), Jaetaek Hwang (Author), Xiaofan Wei (Author), Hyunsoo Kim (Author), Jinbae Son (Author), Sang-Jae Rhee (Author), Kyeong-Ho Yun (Author), Seok-Kyu Oh (Author), Chang-Myung Oh (Author), Raekil Park (Author)
• Format: Book
• Published: MDPI AG, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Although cancer-therapy-related cardiac dysfunction (CTRCD) is a critical issue in clinical practice, there is a glaring lack of evidence regarding cardiotoxicity management. To determine an effective and suitable dosage of treatment using angiotensin receptor-neprilysin inhibitors (ARNI) with sodiu...